Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

✍ Scribed by Karl S Peggs; Sergio A Quezada; Alan J Korman; James P Allison

• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 416 KB
• Volume: 18
• Category: Article
• ISSN: 0952-7915
• DOI: 10.1016/j.coi.2006.01.011

✦ Synopsis

Cytotoxic T lymphocyte antigen-4 has become recognized as one of the key negative regulators of adaptive immune responses, having a central role in the maintenance of peripheral tolerance and in shaping the repertoire of emergent T cell responses. Concurrent recognition of the potential importance of inhibitory immune regulators in limiting antitumor responses, either as a result of chronic antigenic stimulation or the self-nature of many tumor-selective target antigens, has led to the development of cytotoxic T lymphocyte antigen-4blocking antibodies as therapeutic anticancer agents. Following extensive preclinical modeling, these agents have entered clinical trials, where they are showing encouraging activity in heavily pretreated patients with advanced-stage disease, particularly with melanoma or renal carcinoma. Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years.